Shares of Misonix, Inc. (NASDAQ:MSON) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus price target of $26.00 for the company, according to Zacks. Zacks has also given Misonix an industry rank of 78 out of 257 based on the ratings given to its competitors.
MSON has been the subject of several recent research reports. Canaccord Genuity started coverage on Misonix in a report on Friday, August 24th. They set a “buy” rating and a $24.00 price objective for the company. Craig Hallum started coverage on Misonix in a research report on Tuesday, September 11th. They set a “buy” rating and a $28.00 target price on the stock. Finally, TheStreet cut Misonix from a “c” rating to a “d+” rating in a research report on Friday, September 7th.
Shares of NASDAQ MSON traded up $1.47 during midday trading on Friday, hitting $16.54. 22,527 shares of the stock traded hands, compared to its average volume of 16,946. Misonix has a one year low of $8.25 and a one year high of $21.43.
Misonix (NASDAQ:MSON) last released its quarterly earnings data on Thursday, November 8th. The medical equipment provider reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.09). The firm had revenue of $9.36 million for the quarter. Misonix had a negative net margin of 23.24% and a negative return on equity of 14.05%.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Recommended Story: Cost of Equity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.